Literature DB >> 24286592

Substance P in heart failure: the good and the bad.

Heather M Dehlin1, Scott P Levick2.   

Abstract

The tachykinin, substance P, is found primarily in sensory nerves. In the heart, substance P-containing nerve fibers are often found surrounding coronary vessels, making them ideally situated to sense changes in the myocardial environment. Recent studies in rodents have identified substance P as having dual roles in the heart, depending on disease etiology and/or timing. Thus far, these studies indicate that substance P may be protective acutely following ischemia-reperfusion, but damaging long-term in non-ischemic induced remodeling and heart failure. Sensory nerves may be at the apex of the cascade of events leading to heart failure, therefore, they make a promising potential therapeutic target that warrants increased investigation.
Copyright © 2013. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Heart failure; Myocardial remodeling; Neuropeptide; Sensory nerve; Substance P; Tachykinin

Mesh:

Substances:

Year:  2013        PMID: 24286592      PMCID: PMC4450674          DOI: 10.1016/j.ijcard.2013.11.010

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  84 in total

1.  Substance P enhances soluble ICAM-1 release from adult rat cardiac fibroblasts by a p42/44 MAPK- and PKC-mediated mechanism.

Authors:  S Sapna; K Shivakumar
Journal:  Cell Biol Int       Date:  2007-01-25       Impact factor: 3.612

2.  Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma.

Authors:  Johan D Boot; Sanne de Haas; Svetlana Tarasevych; Christine Roy; Lin Wang; Dilip Amin; Judith Cohen; Peter J Sterk; Barry Miller; Anne Paccaly; Jacobus Burggraaf; Adam F Cohen; Zuzana Diamant
Journal:  Am J Respir Crit Care Med       Date:  2006-12-14       Impact factor: 21.405

3.  Differential expression of vesicular glutamate transporters by vagal afferent terminals in rat nucleus of the solitary tract: projections from the heart preferentially express vesicular glutamate transporter 1.

Authors:  E K A Corbett; J K Sinfield; P N McWilliam; J Deuchars; T F C Batten
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

4.  Peptidergic innervation (substance P) in the human heart.

Authors:  E Weihe; M Reinecke; D Opherk; W G Forssmann
Journal:  J Mol Cell Cardiol       Date:  1981-03       Impact factor: 5.000

5.  Immunohistochemical characterization of the intrinsic cardiac neural plexus in whole-mount mouse heart preparations.

Authors:  Kristina Rysevaite; Inga Saburkina; Neringa Pauziene; Raimundas Vaitkevicius; Sami F Noujaim; José Jalife; Dainius H Pauza
Journal:  Heart Rhythm       Date:  2011-01-11       Impact factor: 6.343

6.  Neurokinin-1 receptor antagonism, aprepitant, effectively diminishes post-operative nausea and vomiting while increasing analgesic tolerance in laparoscopic gynecological procedures.

Authors:  Nami Kakuta; Yasuo M Tsutsumi; Yousuke T Horikawa; Hiroaki Kawano; Michiko Kinoshita; Katsuya Tanaka; Shuzo Oshita
Journal:  J Med Invest       Date:  2011-08

7.  The distribution of substrate P-like immunoreactive nerves in the guinea-pig heart.

Authors:  J Wharton; J M Polak; G P McGregor; A E Bishop; S R Bloom
Journal:  Neuroscience       Date:  1981       Impact factor: 3.590

8.  Loss of neutral endopeptidase activity contributes to neutrophil activation and cardiac dysfunction during chronic hypomagnesemia: Protection by substance P receptor blockade.

Authors:  I Tong Mak; Joanna J Chmielinska; Jay H Kramer; Christopher F Spurney; William B Weglicki
Journal:  Exp Clin Cardiol       Date:  2011

9.  Distribution of the neuropeptide galanin in the cat heart and coexistence with vasoactive intestinal peptide, substance P and neuropeptide Y.

Authors:  W Zhu; R D Dey
Journal:  J Mol Cell Cardiol       Date:  1992-01       Impact factor: 5.000

10.  Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart.

Authors:  Scott P Levick; David B Murray; Joseph S Janicki; Gregory L Brower
Journal:  Hypertension       Date:  2010-01-04       Impact factor: 10.190

View more
  24 in total

1.  Innervation of the rabbit cardiac ventricles.

Authors:  Neringa Pauziene; Paulius Alaburda; Kristina Rysevaite-Kyguoliene; Audrys G Pauza; Hermanas Inokaitis; Aiste Masaityte; Gabriele Rudokaite; Inga Saburkina; Jurgita Plisiene; Dainius H Pauza
Journal:  J Anat       Date:  2015-10-29       Impact factor: 2.610

2.  Substance P induces cardioprotection in ischemia-reperfusion via activation of AKT.

Authors:  Shaiban Jubair; Jianping Li; Heather M Dehlin; Edward J Manteufel; Paul H Goldspink; Scott P Levick; Joseph S Janicki
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-06-12       Impact factor: 4.733

Review 3.  The role of neuropeptides in adverse myocardial remodeling and heart failure.

Authors:  Alexander Widiapradja; Prasad Chunduri; Scott P Levick
Journal:  Cell Mol Life Sci       Date:  2017-01-17       Impact factor: 9.261

Review 4.  Histamine receptors in heart failure.

Authors:  Scott P Levick
Journal:  Heart Fail Rev       Date:  2021-10-08       Impact factor: 4.654

5.  Direct activation of tachykinin receptors within baroreflex afferent pathway and neurocontrol of blood pressure regulation.

Authors:  Mei Yuan; Mei-Na Ma; Ting-Yu Wang; Yan Feng; Pei Chen; Chao He; Sijie Liu; Yun-Xia Guo; Yue Wang; Yao Fan; Lu-Qi Wang; Xiao-Qiang E; Guo-Fen Qiao; Bai-Yan Li
Journal:  CNS Neurosci Ther       Date:  2018-06-13       Impact factor: 5.243

6.  Substance P-mediated cardiac mast cell activation: An in vitro study.

Authors:  Scott P Levick; Gregory L Brower; Joseph S Janicki
Journal:  Neuropeptides       Date:  2019-01-08       Impact factor: 3.286

7.  Doxorubicin-Induced Myocardial Fibrosis Involves the Neurokinin-1 Receptor and Direct Effects on Cardiac Fibroblasts.

Authors:  Scott P Levick; David R Soto-Pantoja; Jianli Bi; W Gregory Hundley; Alexander Widiapradja; Edward J Manteufel; Tancia W Bradshaw; Giselle C Meléndez
Journal:  Heart Lung Circ       Date:  2018-09-02       Impact factor: 2.975

8.  DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment.

Authors:  Jessica R Wilson; Erica M Garner; Mona Mashayekhi; Scott A Hubers; Claudia E Ramirez Bustamante; Scott Jafarian Kerman; Hui Nian; Cyndya A Shibao; Nancy J Brown
Journal:  Hypertension       Date:  2022-01-20       Impact factor: 9.897

Review 9.  Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure.

Authors:  Thiago A Salles; Leonardo dos Santos; Valério G Barauna; Adriana C C Girardi
Journal:  Int J Mol Sci       Date:  2015-02-16       Impact factor: 5.923

Review 10.  Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection.

Authors:  Marina Rankovic; Nevena Jeremic; Ivan Srejovic; Katarina Radonjic; Aleksandra Stojanovic; Milos Glisic; Stefani Bolevich; Sergey Bolevich; Vladimir Jakovljevic
Journal:  Heart Fail Rev       Date:  2021-03       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.